Skip to main content

KYMRIAH (Novartis Pharmaceuticals Australia Pty Ltd)

Product name
Date registered
Evaluation commenced
Decision date
Approval time
45 working days (255)
Active ingredients
T Cells - Tisagenlecleucel, cryopreserved - T - Kymriah
Registration type
Class 4 biological

KYMRIAH is a genetically modified autologous immunocellular therapy indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. Kymriah is not indicated for patients with primary central nervous system lymphoma.

Help us improve the Therapeutic Goods Administration site